Vicki Sato Net Worth

The estimated Net Worth of Vicki L Sato is at least $19.3 Milion dollars as of 3 September 2024. Vicki Sato owns over 3,080 units of Vir Biotechnology Inc stock worth over $909,658 and over the last 21 years he sold VIR stock worth over $17,148,918. In addition, he makes $1,267,800 as Independent Chairman of the Board at Vir Biotechnology Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Vicki Sato VIR stock SEC Form 4 insiders trading

Vicki has made over 132 trades of the Vir Biotechnology Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 3,080 units of VIR stock worth $77,000 on 3 September 2024.

The largest trade he's ever made was exercising 46,709 units of Vir Biotechnology Inc stock on 26 November 2003 worth over $368,067. On average, Vicki trades about 4,807 units every 37 days since 2003. As of 3 September 2024 he still owns at least 116,176 units of Vir Biotechnology Inc stock.

You can see the complete history of Vicki Sato stock trades at the bottom of the page.

Vicki Sato biography

Dr. Vicki L. Sato Ph.D. serves as Independent Chairman of the Board of the Company. She was a professor of management practice at Harvard Business School from September 2006 to July 2017 and was a professor in the Department of Molecular and Cell Biology at Harvard University from July 2005 until October 2015. Previously, she served as President of Vertex Pharmaceuticals, Inc. (“Vertex”), a publicly-traded biotechnology company, which she joined in 1992. Prior to becoming President of Vertex, she was the Chief Scientific Officer and Senior Vice President of Research and Development. Prior to joining Vertex, Dr. Sato served as Vice President of Research at Biogen. Dr. Sato is a member of the board of directors of the following public companies: Bristol Myers Squibb Company, BorgWarner, Inc., Denali Therapeutics, Inc., and Syros Pharmaceuticals, Inc. Dr. Sato received her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University. She conducted her postdoctoral work at both the University of California, Berkeley and Stanford Medical Center.

What is the salary of Vicki Sato?

As the Independent Chairman of the Board of Vir Biotechnology Inc, the total compensation of Vicki Sato at Vir Biotechnology Inc is $1,267,800. There are 3 executives at Vir Biotechnology Inc getting paid more, with George Scangos having the highest compensation of $3,944,610.

How old is Vicki Sato?

Vicki Sato is 71, he's been the Independent Chairman of the Board of Vir Biotechnology Inc since 2016. There are 3 older and 19 younger executives at Vir Biotechnology Inc. The oldest executive at Vir Biotechnology Inc is Phillip Sharp, 75, who is the Independent Director.

What's Vicki Sato's mailing address?

Vicki's mailing address filed with the SEC is C/O DENALI THERAPEUTICS INC., 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Vir Biotechnology Inc

Over the last 5 years, insiders at Vir Biotechnology Inc have traded over $197,171,926 worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth $139,246,875 . The most active insiders traders include Norbert W Bischofberger, Endurance (Cayman) Ltd Sb I... a Kristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of $478,115. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth $95,082.

What does Vir Biotechnology Inc do?

vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.

Complete history of Vicki Sato stock trades at Alnylam Pharmaceuticals Inc, Infinity Pharmaceuticals, Syros Pharmaceuticals, Vertex Pharmaceuticals, BorgWarner Inc, Bristol-Myers Squibb Co, Revvity, Denali Therapeutics Inc, Allogene Therapeutics Inc, Vir Biotechnology Inc a Akouos

Vir Biotechnology Inc executives and stock owners

Vir Biotechnology Inc executives and other stock owners filed with the SEC include:

• George Scangos,
  President, Chief Executive Officer, Director
• Howard Horn,
  Chief Financial Officer, Secretary
• Herbert Virgin,
  Executive Vice President of Research and Chief Scientific Officer
• Vicki Sato,
  Independent Chairman of the Board
• Dr. Herbert W. Virgin IV, M.D., Ph.D.,
  Exec. VP of Research & Chief Scientific Officer
• Dr. Herbert W. Virgin IV,
  Exec. VP of Research & Chief Scientific Officer
• Dr. George A. Scangos Ph.D.,
  Pres, CEO & Director
• Dr. Ann M. Hanly Ph.D.,
  Exec. VP & Chief Technology Officer
• Phil Pang,
  Chief Medical Officer
• Dr. George A. Scangos,
  Pres, CEO & Director
• Dr. Phillip Pang M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Steven J. Rice,
  Chief Admin. Officer
• Saira Ramasastry,
  Independent Director
• Robert Perez,
  Independent Director
• Phillip Sharp,
  Independent Director
• Dr. Klaus Frueh,
  Co-Founder & Scientific Advisor
• Robert More,
  Independent Director
• Dipchand Nishar,
  Independent Director
• Robert Nelsen,
  Independent Director
• Elliott Sigal,
  Independent Director
• Janet Napolitano,
  Director
• Michael Kamarck,
  Chief Technology Officer
• Jay Parrish,
  Chief Business Officer
• Johanna Friedl-Naderer,
  Exec. VP & COO
• Irene Pleasure J.D., Ph.D.,
  Sr. VP & Gen. Counsel
• Heather Rowe Armstrong,
  VP of Investor Relations
• Dr. Aine M. Hanly Ph.D.,
  Chief Technology Officer
• Dr. Louis J. Picker M.D.,
  Co-Founder & Scientific Advisor
• Dr. Klaus Frueh Ph.D.,
  Co-Founder & Scientific Advisor
• Dr. Neera Dahiya Ravindran M.D., MBA,
  VP and Head of Investor Relations & Strategic Communications
• Dr. Louis J. Picker,
  Co-Founder & Scientific Advisor
• Dr. Lawrence Corey,
  Co-Founder & Scientific Advisor
• Permanent Fund Corp Alaska,
  
• & Melinda Gates Foundation ...,
  
• Johanna Friedl Naderer,
  EVP & Chief Operating Officer
• Steven J. Rice,
  Chief Administrative Officer
• Venture Partners Ix, Llcarc...,
  
• Endurance (Cayman) Ltd Sb I...,
  
• Dhabi Investment Authority ...,
  
• Holdings (Private) Ltd Full...,
  
• Program Ii (Co Invest Holdi...,
  
• Mark Eisner,
  EVP and Chief Medical Officer
• Klaus Frueh,
  Director
• Venture Partners Ix, Llcarc...,
  
• Kristina Burow,
  Director
• Jeffrey S. Hatfield,
  Director
• Norbert W Bischofberger,
  Director
• Ramy Farid,
  Director
• Sung Lee,
  EVP & Chief Financial Officer
• Ann M. Hanly,
  EVP & Chief Technology Officer
• Backer Marianne De,
  Chief Executive Officer